Double-Blind, Randomized, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of ATHX-105 Phosphate for the Treatment of Obesity

Healios K.K.0 个研究点开始时间: 2008年9月最近更新: 2015年6月2日

适应症

干预措施

试验速览

阶段: 2 期
状态: 撤回
发起方: Healios K.K.
主要终点: Change in body weight

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This primary purpose of this study is to determine if ATHX-105 phosphate causes weight loss over a 12-week period.

详细描述

The rate of obesity in adults continues to increase. Obesity affects overall health and is associated with an increased risk for diabetes, high blood pressure, coronary artery disease, osteoarthritis, and sleep apnea. To date, the medication options to treat obesity have been limited.

This study will examine if a new investigational drug, ATHX-105 phosphate, may cause weight loss in humans over a 12-week period.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Obese adults with a body mass index of 30-45 kg/m2

排除标准

•Pregnancy
•Adults with serious or unstable current or past medical conditions

研究组 & 干预措施

1

Placebo Comparator

干预措施: Placebo (Drug)